PMID- 10218103
OWN - NLM
STAT- MEDLINE
DCOM- 19990610
LR  - 20191103
IS  - 0065-230X (Print)
IS  - 0065-230X (Linking)
VI  - 76
DP  - 1999
TI  - Antitumor immunity at work in a melanoma patient.
PG  - 213-42
AB  - This review covers the results obtained so far with a chronological analysis of
      the antitumor cytolytic T lymphocyte (CTL) cell response of a melanoma patient
      who enjoys an unusually favorable evolution. Two melanoma cell lines, MEL.A and
      MEL.B, were derived from metastases removed from the patient in 1988 and 1993,
      respectively. The patient developed a very strong CTL response against the MEL.A 
      cells. Several antigens on these cells, presented by various HLA class I
      molecules, result from point mutations present in the genome of the tumor. The
      MEL.B cells, on the other hand, resist lysis by these CTLs because they have lost
      expression of most HLA class I molecules, suggesting that they were selected in
      vivo by the anti-MEL.A CTLs. New CTLs recognize MEL.B cells specifically,
      however. Analysis of their specificity indicates that they carry inhibitory
      receptors similar to those present on natural killer (NK) cells. These results
      illustrate the relationship between a tumor and the immune system in vivo over a 
      period of several years. They are discussed in the context of the recent
      identification of many human tumor antigens recognized by CTLs, and the
      perspectives of specific immunotherapy opened up by these discoveries.
FAU - Coulie, P G
AU  - Coulie PG
AD  - Catholic University of Louvain, Cellular Genetics Unit, Brussels, Belgium.
FAU - Ikeda, H
AU  - Ikeda H
FAU - Baurain, J F
AU  - Baurain JF
FAU - Chiari, R
AU  - Chiari R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Cancer Res
JT  - Advances in cancer research
JID - 0370416
RN  - 0 (Receptors, Immunologic)
SB  - IM
MH  - Cytotoxicity, Immunologic
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Melanoma/*immunology/pathology
MH  - Neoplasm Metastasis
MH  - Receptors, Immunologic/physiology
MH  - Skin Neoplasms/*immunology/pathology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
RF  - 69
EDAT- 1999/04/28 00:00
MHDA- 1999/04/28 00:01
CRDT- 1999/04/28 00:00
PHST- 1999/04/28 00:00 [pubmed]
PHST- 1999/04/28 00:01 [medline]
PHST- 1999/04/28 00:00 [entrez]
AID - S0065-230X(08)60778-2 [pii]
AID - 10.1016/s0065-230x(08)60778-2 [doi]
PST - ppublish
SO  - Adv Cancer Res. 1999;76:213-42. doi: 10.1016/s0065-230x(08)60778-2.